-
TD Cowen Starts MapLight Therapeutics (MPLT) at Buy
-
Stifel stays Buy rated on MapLight Therapeutics (MPLT) after in-line Q4 update
-
Canaccord Starts MapLight Therapeutics (MPLT) at Buy
-
MapLight Therapeutics gets FDA fast track status for Alzheimer's drug
-
Jefferies on MapLight Therapeutics (MPLT): 'Cleaner Catalyst Flow as Competitor Pushes Back Alz Psychosis Data to YE:26'
-
Leerink Partners Starts MapLight Therapeutics (MPLT) at Outperform
-
Jefferies Starts MapLight Therapeutics (MPLT) at Buy
-
Stifel Starts MapLight Therapeutics (MPLT) at Buy
-
Morgan Stanley Starts MapLight Therapeutics (MPLT) at Overweight
-
MapLight (MPLT) reportedly to stop taking IPO orders at noon Thursday
-
MapLight Therapeutics IPO reportedly well oversubscribed
-
MapLight Therapeutics files for 14.75M share IPO at $17/sh
-
MapLight (MPLT) files for proposed Nasdaq IPO

